UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2024

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-40522**	**84-3766197**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

321 Harrison Avenue, Suite 900
Boston, MA 02118
(Address of principal executive offices, including zip code)

(617) 949-2643
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	**GLUE**	**The Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure

On December 5, 2024, Monte Rosa Therapeutics, Inc. (the "Company") issued a press release titled "Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors". The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On December 5, 2024, the Company also issued a corporate presentation that it intends to utilize in various meetings with securities analysts, investors and others. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events

On December 5, 2024, the Company reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors.

Summary of Interim Data on Enrollment, Safety & Pharmacodynamics

Enrollment Highlights

- Patients have been dosed with MRT-2359 in 6 dose levels across two dosing schedules, namely a 5 days on, 9 days off drug (5/9) dosing schedule and a 21 days on, 7 days off drug (21/7) dosing schedule.
- The study has enrolled patients with a diverse set of tumor types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), neuroendocrine (NE) tumors of the prostate, bladder and other organs of origin, androgen receptor-positive prostate cancer, and estrogen receptor-positive breast cancer.

Safety Highlights

- Using the 5/9 dosing schedule, doses of 0.5 mg and 1 mg per day were identified as having a generally favorable safety profile, while doses of 1.5 mg or higher were above the maximum tolerated dose (MTD) with thrombocytopenia being a dose limiting toxicity (DLT).
- Using the 21/7 schedule, both 0.5 and 0.75 mg were identified as having a generally favorable safety profile.
- 0.5 mg using the 21/7 dose schedule was selected as the recommended phase 2 dose (RP2D) for any expansion cohorts of the Phase 1/2 study.
- Safety assessments of MRT-2359 in combination with enzalutamide in previously treated metastatic prostate cancer as well as with fulvestrant in previously treated metastatic estrogen receptor-positive breast cancer have been initiated.
- No signs of hypotension, cytokine release syndrome or clinically significant hypocalcemia observed at any dose level and regimen.

Pharmacodynamic Highlights

- Pharmacodynamic effects were assessed utilizing mass spectrometry measurements of GSPT1 protein levels from paired tumor biopsies. The target levels of approximately 60% GSPT1 degradation were observed in tumor biopsies across all dose levels in relevant tumor types, supporting that the dose of 0.5 mg per day provides optimal degradation consistent with its designed activity based on preclinical studies.

Monte Rosa continues to collect and evaluate clinical results from the MRT-2359 Phase 1/2 study and expects to share updated data, including biomarker and activity data, in Q1 2025.

Forward-Looking Statements

This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ongoing clinical development of our GSPT1 degrader referred to as MRT-2359, including our expectations for the nature, efficiency of clinical trial design, significance, and timing for our disclosure of any updated data from our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the first quarter of 2025, the timing of enrollment of potential Phase 2 expansion cohorts and around the potential of the recommended Phase 2 dose for MRT-2359 to have a generally favorable safety profile and be more patient compliance friendly, expectation that clinical results will support MRT-2359's

safety and activity profile, statements around the advancement and application of our pipeline and platform, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights, our expectations of success for our programs, among others.

By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on March 14, 2024, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1	Press Release issued by Monte Rosa Therapeutics, Inc. dated December 5, 2024.
99.2	Corporate Presentation furnished by Monte Rosa Therapeutics, Inc. on December 5, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Monte Rosa Therapeutics, Inc.

Date: December 5, 2024

By: /s/ Markus Warmuth
Markus Warmuth
President and Chief Executive Officer

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients

Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule

Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025

BOSTON, Mass., December 5, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa Therapeutics.

"These latest interim results from our ongoing Phase 1/2 study of MRT-2359 continue to indicate a favorable safety profile, and degradation of GSPT1 to desired levels in patients with heavily pretreated, solid tumors, including those that express high levels of MYC. Importantly, we believe the MRT-2359 safety profile supports further clinical development, with no signs of hypotension, cytokine release syndrome (CRS), or clinically significant hypocalcemia observed at any dose level and regimen, all of which have been reported as safety limitations of other GSPT1 degraders. We're pleased to confirm the selection of 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule as our recommended Phase 2 dose, a schedule that enables dosing of MRT-2359 more than twice as frequently per cycle as compared to the 5 days on, 9 days off regimen previously explored in our study and that we also believe to be more patient compliance-friendly," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Trial enrollment has been strong and we are working towards completing the biomarker and activity assessment of our monotherapy dose escalation study using the 21 days on, 7 days off schedule, including backfill cohorts. We have started safety assessments of MRT-2359 in combination with enzalutamide in previously treated metastatic prostate cancer patients as well as with fulvestrant in previously treated metastatic estrogen receptor-positive breast cancer patients. We look forward to providing an update on clinical data from the study as well as plans for potential expansion cohorts in the first quarter of next year."

Summary of Interim Data on Enrollment, Safety & Pharmacodynamics

Enrollment Highlights

- Patients have been dosed with MRT-2359 in 6 dose levels across two dosing schedules, namely a 5 days on, 9 days off drug (5/9) dosing schedule and a 21 days on, 7 days off drug (21/7) dosing schedule.
- The study has enrolled patients with a diverse set of tumor types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), neuroendocrine (NE) tumors of the prostate, bladder

and other organs of origin, androgen receptor-positive prostate cancer, and estrogen receptor-positive breast cancer.

Safety Highlights

- Using the 5/9 dosing schedule, doses of 0.5 mg and 1 mg per day were identified as having a generally favorable safety profile, while doses of 1.5 mg or higher were above the maximum tolerated dose (MTD) with thrombocytopenia being a dose limiting toxicity (DLT).
- Using the 21/7 schedule, both 0.5 and 0.75 mg were identified as having a generally favorable safety profile.
- 0.5 mg using the 21/7 dose schedule was selected as the recommended phase 2 dose (RP2D) for any expansion cohorts of the Phase 1/2 study.
- Safety assessments of MRT-2359 in combination with enzalutamide in previously treated metastatic prostate cancer as well as with fulvestrant in previously treated metastatic estrogen receptor- positive breast cancer have been initiated.

Pharmacodynamic Highlights

- Pharmacodynamic effects were assessed utilizing mass spectrometry measurements of GSPT1 protein levels from paired tumor biopsies. The target levels of approximately 60% GSPT1 degradation were observed in tumor biopsies across all dose levels in relevant tumor types, supporting that the dose of 0.5 mg per day provides optimal degradation consistent with its designed activity based on preclinical studies.

Monte Rosa continues to collect and evaluate clinical results from the MRT-2359 Phase 1/2 study and expects to share updated data, including biomarker and activity data, in Q1 2025.

About MRT-2359

MRT-2359 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein. The MYC transcription factors (c-MYC, L-MYC and N-MYC) are well-established drivers of human cancers that maintain high levels of protein translation, which is critical for uncontrolled cell proliferation and tumor growth. Preclinical studies have shown this addiction to MYC-induced protein translation creates a dependency on GSPT1. By inducing degradation of GSPT1, MRT-2359 is designed to exploit this vulnerability, disrupting the protein synthesis machinery, leading to anti-tumor activity in MYC-driven tumors.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans

oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Forward-Looking Statements

This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline and to broaden the scope of clinical development of MRT-2359 across a range of conditions, statements around the Company's QuEEN™ discovery engine and the Company's view of its potential to identify degradable protein targets and rationally design MGDs with unprecedented selectivity, statements around the productivity of the QuEEN discovery engine and the potential of the Company's MGDs against a broad spectrum of targets, statements about the advancement and timeline of our preclinical and clinical programs and pipeline, our ongoing clinical development of our GSPT1 degrader referred to as MRT-2359, including our expectations for the nature, efficiency of clinical trial design, significance, and timing for our disclosure of any updated data from our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the first quarter of 2025, the timing of enrollment of potential Phase 2 expansion cohorts in the first quarter of 2025 and around the potential of the recommended Phase 2 dose for MRT-2359 to have a generally favorable safety profile and be more patient compliance friendly, statements around the Company's ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of its clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support MRT-2359's safety and activity profile; statements around the advancement and application of our pipeline and platform, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights, our expectations of success for our programs, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on March 14, 2024, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not

independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

###


From Serendipity to Rational Design
Taking Molecular Glue Degraders to New Heights | December 2024
Monte Rosa Therapeutics

Forward-Looking Statements

This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, statements around the Company's QuEEN™ discovery engine and the Company's view of its potential to identify degradable protein targets and rationally design MGDs with unprecedented selectivity, statements related to the Company's strategic agreements, goals of such agreements, including the ability to accelerate and broaden scope of clinical development of MRT-6160 while retaining substantial value for the Company, as well as to expand platform reach to discover and develop MGDs against previously undruggable targets in cancer and neurological diseases, statements related to any milestone provided under the strategic agreements, royalty or other payments related thereto and the ability of such payments to extend our runway, statements around the productivity of the QuEEN discovery engine and the potential of the Company's MGDs against a broad spectrum of targets, statements about the advancement and timeline of its preclinical and clinical programs, pipeline and the various products therein, statements around multiple anticipated preclinical and/or clinical readouts and their expected timing, including results from proof-of-concept patient studies, statements related to regulatory submissions, including timing thereof, and interactions with regulatory authorities, the applicability of candidates to various indications, the expected potential clinical benefit of any of our candidates, statements around advancement and application of our pipeline and application of our platform, statements concerning our expectations regarding our ability to identify, nominate and the timing of our nominations of additional targets, product candidates, and development candidates, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights as well as our the ability to optimize collaborations with industry partners on our development programs, statements about the closing of the transaction with Novartis, obligations under our collaboration agreements, expectations around the receipt of any payments under such agreements and the future development and commercialization of various products, our use of capital, expenses and other financial results in the future, availability of funding for existing programs, ability to fund operations into 2028 through multiple anticipated proof-of-concept patient study readouts, inclusive of the upfront payment from Novartis, as well as our expectations of success for our programs, strength of collaboration relationships and the strength of our financial position, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on March 14, 2024, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research. These materials remain the proprietary intellectual property of Monte Rosa Therapeutics and should not be distributed or reproduced in whole or in part without the prior written consent of Monte Rosa Therapeutics.

Monte Rosa Therapeutics – Company Overview

Taking molecular glue degraders (MGDs) to new heights

Arsenal of rationally designed MGDs with potential to solve many of the limitations of other modalities by degrading therapeutically relevant proteins with unprecedented precision

Highly productive**, industry-leading discovery engine** combining experimentation **with AI to enable rational design of novel MGDs**

Collaboration with Roche to develop MGDs for oncology and neurological conditions **– expands platform reach into neurology**

Phase 1/2 clinical study ongoing with MRT-2359 in MYC-driven cancers; interim data demonstrated optimal pharmacodynamic modulation and **early signs of clinical activity; additional Phase 1 data expected Q1 2025**

MRT-6160, highly selective VAV1-directed MGD, in Phase 1 study, data expected Q1 2025; broad potential applications across autoimmune diseases **– global license to Novartis* with US P&L share**

MRT-8102, highly selective NEK7-directed MGD for IL-1β/NLRP3-driven inflammatory diseases with IND submission anticipated H1 2025

Strong financial position providing cash runway into 2028 through multiple anticipated proof-of-concept clinical readouts

* Subject to customary closing conditions, including regulatory clearance.

Three Ways to Eliminate a Disease-Causing Protein

MGDs can directly and precisely target proteins that cause disease



Our Molecular Glue Degraders (MGDs) Edit the Proteome



Monte Rosa's rationally designed MGDs have potential applications in Oncology, Immunology, Neuroscience and other therapeutic areas

Molecular Glue Degraders (MGDs) – A Highly Differentiated Modality

Advantages of large molecule modalities with orally dosed small molecules



Key Advantages of Our Rationally Designed MGDs

Unique Target Space



Disease-agnostic platform with initial focus on highly credentialed, undruggable oncology and immunology/inflammation targets

Unprecedented Selectivity



Unique insights into anatomy of protein-protein-MGD interaction allows unprecedented MGD selectivity

Catalytic Mechanism of Action



Long lasting, catalytic protein degradation effect creates differentiated target product profiles

POI = protein of interest

Monte Rosa Therapeutics

Portfolio and Partnerships

Monte Rosa Pipeline and Upcoming Milestones

Target	Compound	Indication(s)	Discovery	IND-Enabling	Clinical	Next Anticipated Milestone	Ownership
GSPT1	MRT-2359	NSCLC, SCLC and other MYC-driven Malignancies				Additional Phase 1 data in Q1 2025	
VAV1	MRT-6160	Autoimmune Disease – Systemic and CNS				Phase 1 data in Q1 2025	NOVARTIS *
NEK7	MRT-8102	IL-1β/NLRP3 driven Inflammatory Diseases				IND submission in H1 2025	
	LO (2nd generation)					Development candidate	
CDK2	LO	Breast Cancer				Development candidate in 2024	
CCNE1 (Cyclin E1)	LO	CCNE1 amplified tumors				Development candidate	
Discovery Targets	-	Multiple				Lead optimization	
Discovery Targets	-	Oncology and Neurological Diseases				Undisclosed	Roche

Oncology Immunology Inflammation Various

* Monte Rosa has signed an exclusive global license agreement with Novartis for this asset. This transaction is subject to customary closing conditions, including regulatory clearance.

Creating Value through Strategic Agreements

	NOVARTIS	Roche
Scope	Global license agreement to advance VAV1-directed molecular glue degraders including MRT-6160 (announced Oct. 2024)	Strategic collaboration to discover novel MGDs targeting cancer and neurological diseases (announced Oct. 2023)
Financials	• $150M upfront payment • Eligible for up to $2.1B in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies • Eligible for US P&L share and ex-US tiered royalties	• $50M upfront payment • Eligible for preclinical, clinical, commercial and sales milestone payments >$2B and tiered royalties
Strategic Goal	Accelerate and broaden scope of clinical development of MRT-6160 while retaining substantial value for Monte Rosa	Expand platform reach to discover and develop MGDs against previously undruggable targets in cancer and neurological diseases

Notes: Novartis agreement is subject to customary closing conditions, including regulatory clearance. Under the terms of the Novartis agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa remains responsible for completion of the ongoing Phase 1 clinical study of MRT-6160. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S. Under the terms of the Roche agreement, Monte Rosa Therapeutics will lead discovery and preclinical activities against multiple select cancer and neurological disease targets to a defined point. Roche gains the right to exclusively pursue further preclinical and clinical development of the compounds.

Monte Rosa Therapeutics

GSPT1 program (MRT-2359)

MYC is a Key Regulator of Cancer Growth and Immune Evasion

- Frequently activated across many cancers including some of the most common (e.g. lung, prostate, breast)
- Drives cancer progression through effects on both cancer cells and tumor microenvironment
- MYC signaling can enable tumor cells to evade immune response
- Very challenging to drug with conventional approaches; no approved MYC-targeted therapies

- MRT-2359 is designed to specifically target MYC-driven tumors



Source: Dhanesekaran R et al. Nat Rev Clin Oncol 2022

Targeting MYC-driven Tumors and Their Addiction to Protein Translation Through GSPT1 Degradation



1

Addiction

To sustain growth, MYC-driven tumors are **addicted to protein translation**

2

Dependency

This addiction creates a dependency on the **translation termination factor GSPT1**

3

Therapeutic vulnerability

GSPT1 is a therapeutic vulnerability of MYC-driven tumors
leading to preferential activity of GSPT1 MGDs

MRT-2359 is a Potent and Highly Selective GSPT1-directed MGD

MRT-2359 is a potent GSPT1-directed MGD

Ternary complex modelling



in vitro data	
CRBN binding, K_i	113 nM
Ternary complex, EC_{50}	< 7 nM
Degradation, DC_{50} (in disease relevant cell lines)	1 - 20 nM

MRT-2359 induces selective GSPT1 degradation and shows favorable ADME/DMPK profile



No degradation of other known cereblon neosubstrates

ADMET profile	
CYP DDIs	> 30 µM
hERG inhibition patch clamp	EC_{50} > 30 µM
Oral bioavailability all species	~50%

MRT-2359 Has Optimized Depth of Degradation To Achieve Preferential Activity in MYC High Cancer Cells



MRT-2359 displays preferential activity in MYC driven NSCLC cells



Non-optimal GSPT1 MGD (MRT-2136) shows limited preferential activity



Three Mechanisms Driving Preferential Activity in MYC High Tumor Cells

Preferential GSPT1 degradation

MRT-2359 leads to deeper degradation of GSPT1 in cancer cells with high MYC expression



Inhibition of translation

MRT-2359-induced reduction of GSPT1 preferentially impairs protein synthesis in tumor cells with high MYC expression



MYC down-modulation

In a feedback loop, MRT-2359 decreases MYC expression and transcriptional activity

Large Potential Opportunities in MYC-Driven Tumors

High unmet need with no currently approved therapies specifically for MYC high tumors



N-MYC High
and/or
L-MYC High

SCLC (70-80% L/N-MYC high)

NSCLC
N-MYC high (5-10%)
SCLC/NE transformation

Neuroendocrine lung cancer



Neuroendocrine tumors

L-/N-MYC amplified tumors





c-MYC High

Prostate cancer
Including ARV7 positive



Breast cancer
ER positive metastatic



Preclinical Validation of Activity of MRT-2359 in Lung Cancer PDX Models



MRT-2359 Leads to Tumor Regressions in Preclinical Models of Castration Resistant Prostate Cancer and ARV7-driven Prostate Cancer

MRT-2359 displays activity in castrate resistant VCAP model



MRT-2359 displays activity in ARV7 driven 22RV1 model



MRT-2359 Leads to Tumor Regressions in Preclinical Model of ER-positive Breast Cancer

MRT-2359 displays activity in MCF7 model of ER-positive breast cancer



MCF7 Breast CDX (ER+, HER2-)

MRT-2359 reduces MYC and CCND1 *in vivo*



MRT-2359-001 Phase 1/2 Clinical Study Design



21

5/9 = 5 days on drug, 9 days off drug
21/7 = 21 days on drug, 7 days off drug
RP2D = recommended Phase 2 dose

MRT-2359 Phase I Interim Data – October 2023

Objectives of Phase I interim analysis

- ✓ Demonstrate dose dependent PK
- ✓ Demonstrate significant GSPT1 degradation at safe dose levels in PBMCs and tissue biopsies (60% based on preclinical data)
- ✓ Share potential preliminary efficacy signals in biomarker positive patients

MRT-2359 Induces Optimal GSPT1 Degradation in PBMCs*

MRT-2359 displayed dose dependent plasma exposure



- Dose dependent exposure in line with preclinical PK models
- No food effect observed

MRT-2359 displayed deep GSPT1 degradation in PBMCs at all dose levels



- GSPT1 expression assessed using targeted mass spectrometry
- PD modulation in PBMCs observed across all dose levels; level of degradation (~ 60%) in line with maximal degradation observed in preclinical studies using the same method
- Level of degradation equivalent across all dose levels, suggesting saturated PD response from 0.5 to 2 mg

* as presented on 10/17/23

MRT-2359 Induces Optimal GSPT1 Degradation in Tissue Biopsies*

MRT-2359 reduced GSPT1 protein expression in human tissue biopsies



- GSPT1 degradation assessed from pre-treatment screening biopsies and biopsies taken at day 19
- Matched biopsies obtained from 11 patients across the 3 cohorts analyzed
- GSPT1 expression assessed using targeted mass spectrometry
- PD modulation seen in tissue biopsies in line with PD modulation seen preclinically at efficacious dose levels using same assay (targeted mass spectrometry)

* Based on optimal PD modulation in preclinical studies as presented on 10/17/23

Summary of Treatment-Related Adverse Events (AEs) in ≥ 2 patients[#]

No observed clinically significant hypocalcemia or hypotension/cytokine release syndrome

AE Preferred Term	0.5 mg (N=9)[##]		1 mg (N=7)[##]		2 mg (N=5) [##]		Overall (N=21)	
	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3
Thrombocytopenia[###]	0	0	0	0	4 (80%)	3 (60%)[***]	4 (19%)	3 (14%)
Neutropenia[*]	0	0	0	0	2 (40%)	1 (20%)	2 (10%)	1 (5%)
Leukopenia	0	0	0	0	2 (40%)	2 (40%)	2 (10%)	2 (10%)
Nausea	3 (33%)	0	2 (29%)	0	1 (20%)	0	6 (33%)	0
Vomiting	1 (11%)	0	2 (29%)	0	1 (20%)	0	4 (19%)	0
Diarrhea[**]	1 (11%)	0	3 (43%)	0	1 (20%)	0	5 (24%)	0
Hypokalemia	0	0	1 (14%)	0	1 (20%)	0	2 (10%)	0
Fatigue	0	0	2 (29%)	0	0	0	2 (10%)	0
Decreased appetite	0	0	2 (29%)	0	0	0	2 (10%)	0
Rash	2 (22%)	0	0	0	0	0	2 (10%)	0

Note: As presented on 10/17/23

[#] Data cut-off: 7 SEP 2023
[##] MRT-2359 was given orally daily on the 5 days on and 9 days off schedule
[###] Data combined for 'thrombocytopenia' and 'platelet count decreased'
[*] Data combined for 'neutropenia' and 'neutrophil count decreased'
[**] Data combined for 'diarrhea' and 'feces soft'
[***] Dose limiting toxicity: Grade 4 thrombocytopenia in 2 patients

Confirmed Partial Response in High Grade Neuroendocrine Bladder Cancer*

- High Grade (HG) neuroendocrine bladder cancer
- Baseline tumor biopsy demonstrated high N-MYC expression
- 4 prior lines of therapy including chemotherapy and pembrolizumab
- Patient initiated on 2 mg for first 5/9 regimen, then lowered to 1 mg and 0.5 mg and remains on therapy (> 3 month)
- CT scan after 4 weeks demonstrated PR (-34% per RECIST 1.1) that continued to improve at week 8 (-59% per RECIST 1.1)



* as presented on 10/17/23

Unconfirmed Partial Response in NSCLC with SCLC/NE Transformation*

- NSCLC (adenocarcinoma)
- Baseline tumor biopsy demonstrated SCLC/NE transformation, low N- and L-MYC expression
- Multiple lines of prior therapy including chemotherapy, pembrolizumab and atezolizumab
- Patient initiated on 0.5 mg
- CT on C1D22 demonstrated resolution of liver metastases (-41% per RECIST 1.1)
- Patient experienced frequent dose interruptions due to bowel obstruction unrelated to MRT-2359



* as presented on 10/17/23

MRT-2359-001 – Preliminary Efficacy Data*

- As of September 7th, 2023, of 15 evaluable patients treated across 3 cohorts, tumors from 6 patients were identified as biomarker positive
- Of these 6 biomarker positive patients, 2 have experienced a PR (1 confirmed, 1 unconfirmed) and 1 patient has SD
  - PR (-59%) – HG NE bladder carcinoma
  - uPR (-41%) – NSCLC with SCLC/NE transformation
  - SD (0%) – SCLC (remains on therapy for > 4 months)
- In addition, one patient with NSCLC and unclear biomarker status remains on therapy for > 7 months with stable disease
- No clinical activity seen in biomarker negative patients



* as presented on 10/17/23

Favorable Safety Profile at Clinically Active Doses*

Safety profile supports further development

- Preferential and more rapid degradation of GSPT1 in MYC high tumor cells enables favorable adverse event (AE) profile at clinically active doses of 0.5 and 1 mg – no Grade ≥3 AEs
  - Grade 1-2 AEs primarily GI-related and manageable
- No observations of previously reported limitations of other GSPT1-targeted agents
  - No observed clinically significant hypocalcemia or hypotension/cytokine release syndrome at any dose level
- Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg
- Favorable safety profile with lack of hypocalcemia has enabled exploration of 21/7 schedule, starting at 0.5 mg
- RP2D expected in Q2 of 2024

* as presented on 10/17/23

Monte Rosa Therapeutics

VAV1 Program (MRT-6160)

VAV1 is a Key Regulator of T- and B-cell Receptor Activity

VAV1-directed MGDs have the potential to modulate T- and B-cell function



VAV1 signaling increases cytokine production, proliferation, and differentiation

Therapeutic hypothesis:

- VAV1 is a pivotal scaffolding protein and signaling molecule downstream of both the T-cell and B-cell receptors – confirmed by multiple CRISPR screens and VAV1 knockout (KO) mice
- VAV1 degradation is predicted to impact both T- & B-cell function and has the potential to treat a broad set of autoimmune diseases

Clinical Opportunity:

Autoimmune/inflammatory disorders including inflammatory bowel disease (4.1M patients), rheumatoid arthritis (6.2M patients), multiple sclerosis (1.3M patients), and myasthenia gravis (~300K patients)

TCR = T-cell receptor. BCR = B-cell receptor. IL-2, IL-17 and IL-6 are cell signaling molecules (cytokines) that promote immune response. sIgG is the most common circulating antibody.

Patient diagnosed prevalence #s, major markets (US, EU and JP): Decision Resources Group (DRG)

VAV1 is an Upstream Targeting Node Associated with Clinically Validated Pathways

VAV1 signaling is associated with several T and B cell immunologic outcomes



VAV1

T cell activation

B cell activation/Plasma cell differentiation (Antibody production)

Th17 response

Pro-inflammatory cytokine production

Clinically validated pathway in autoimmune/inflammatory disease

ORENCIA® (abatacept)

RINVOQ® upadacitinib

Rituxan® Rituximab

VYVGART® Hytrulo

Cosentyx® (secukinumab)

omvoh™ (mirikizumab-mrkz) 300 mg/15 mL infusion | 100 mg/mL injection

HUMIRA® adalimumab

ACTEMRA® tocilizumab

MRT-6160 is a Potent and Highly Selective VAV1-directed MGD

MRT-6160 is a potent VAV1-directed MGD



in vitro data	
CRBN binding, IC_{50}	670 nM
Ternary complex, EC_{50}	11 nM
Degradation, DC_{50} /D_{max} (Jurkat)	7 nM / 97 %

MRT-6160 induces highly selective VAV1 degradation and has a favorable ADME/DMPK profile



No degradation of other known cereblon neosubstrates

ADMET profile	
CYP DDIs	IC_{50} > 30 µM
hERG inhibition patch clamp	EC_{50} > 30 µM
Oral bioavailability all species	> 50%

MRT-6160 is a Potent, Highly Selective VAV1 MGD with a Favorable Drug-like Profile

VAV1 ternary complex (Cryo-EM)



Cryo-EM structure of MRT-6160 in ternary complex with CRBN and VAV1

MGD Activity Profile	
CRBN Binding (HTRF, IC_{50})	0.67 µM
VAV1 Ternary Complex (HTRF, EC_{50})	11 nM
VAV1 Degradation (Jurkat, DC_{50} /Dmax)	7 nM / 97%
Selectivity (TMT proteomics)	Large VAV1 selectivity window
Physicochemical Properties	
LogD	1.5
MW	<400
Thermodynamic Solubility	7 µM
ADMET Profile	
Oral bioavailability (all species)	> 50 %
Metabolite Profile (*in vitro*)	No unique human metabolites or GSH adducts (mics)
CYP DDI (9 isoforms)	IC_{50} > 30 µM
Safety Pharmacology	
Mini-Ames	Negative
hERG inhibition (patch clamp)	No inhibition (EC_{50} > 30 µM)
Counterscreens (panel with 98 targets)	No inhibition

28-day GLP Toxicology Studies Establish Highly Favorable Safety Margins

28-day GLP Toxicology Summary

- 28-day GLP Rat and Cyno studies completed with NOAEL set at the highest doses in both species
  - Rats: NOAEL is ~1000-fold over the projected human efficacious exposure
  - Cyno: NOAEL is ~600-fold over the projected human efficacious exposure
- No adverse immunotoxicity or impact on peripheral immune compartments in healthy cynomolgus monkeys
- No impact on bone marrow, peripheral hematopoietic cells counts, GI tract
- No off-targets identified in *in-vitro* safety profiling, no genotoxicity, phototoxicity, or hERG activity

Robust VAV1 degradation and recovery observed in both low and high dose groups in cyno GLP tox study



**data shown from female cyno PBMCs, similar data obtained in males*

NOAEL = no observed adverse effect level

MRT-6160 Blocks T-cell-Mediated B-cell Activity in BioMAP® Profile



BioMAP® Diversity Plus Platform (Eurofins). Shark tooth plots show relative expression levels of indicated proteins in Drug treated vs. DMSO controls. 3C/4H, Venular endothelial cells; LPS/SAg, Venular endothelial cells + PBMC; BT, PBMC + B cells; BF4T, Bronchial epithelial cells + dermal fibroblasts; BE3C. Bronchial epithelial cells; CASM3C, Coronary artery smooth muscle cells; HDF5CGF, Dermal fibroblasts; KF3CT, keratinocytes + dermal fibroblasts; MyoF, lung fibroblasts; IMphg, macrophages + venular epithelial cells

MRT-6160 Ameliorates T Cell Transfer-Induced Colitis Better than Standard of Care

Treatment initiated at time of model induction on Day 0



Treatment initiated in therapeutic setting on Day 17 following disease induction



Non-pathogenic CD45RB^{low} or pathogenic CD45RB^{high} cells were transferred into SCID mice to induce colitis. Mice were treated with vehicle, MRT-6160 (PO QD), or anti-TNF (IP Q3D) from Day 0 to Day 42 and assessed for disease every 3 days (*left*) or with vehicle, MRT-6160, or S1PR antagonist (etrasimod; PO QD), or JAKi (upadacitinib; PO BID) from Day 17 to Day 45 and assessed for disease every 3 days (*right*)

MRT-6160 Reduces Inflammation-Mediated Damage of the Colon and Cytokine Production in a T-Cell Transfer Model of Ulcerative Colitis

MRT-6160 reduces inflammation-mediated damage and swelling of the colon



Hematoxylin and eosin-stained histopathology sections from colon at end of study

MRT-6160 reduces cytokine production in the mesenteric lymph node and colon



Flow cytometric (*upper row*) and cytokine bead array (*lower row*) analysis of mesenteric lymph node CD4+ T cells and colon tissue respectively

MRT-6160 Reduces Expression of Human Disease-Relevant Pro-Inflammatory and Disease-Associated Genes

MRT-6160 attenuates expression of a pro-inflammatory disease gene signature



RNA from mouse colon at study termination was assessed using the NanoString nCounter Mouse Autoimmune Profiling Panel

MRT-6160 attenuates expression of human Ulcerative Colitis-relevant pro-inflammatory genes



Vehicle vs. Control differential expression in the IBD mouse model was mapped to human ulcerative colitis vs healthy differential expression



MRT-6160 vs Vehicle differential expression in the IBD mouse model was mapped to human ulcerative colitis vs healthy differential expression

MRT-6160 Inhibits Disease Progression, Joint Inflammation & Auto-Antibody Production in a Rheumatoid Arthritis Disease Model

MRT-6160 inhibits disease progression



MRT-6160 inhibits anti-collagen II auto-antibodies



Collagen-induced arthritis T/B-cell (auto-antibody) driven model

Mice were immunized with bovine collagen II twice 21 days apart and enrolled into treatment groups at disease onset

Dosing: Vehicle, MRT-6160, or anti-TNF (IP BIW) for 22 days starting at disease onset

MRT-6160 Reduces Pro-Inflammatory Cytokine Production in a Rheumatoid Arthritis Disease Model



Collagen-induced arthritis T/B-cell (auto-antibody) driven model
Dosing: Vehicle, MRT-6160; PO QD. Anti-TNF; IP BIW.
Mice were treated for 21 days from disease onset (Day 0)
Serum cytokine analysis on Day 21

MRT-6160 Elicits Dose-Dependent Activity in T-cell-mediated Multiple Sclerosis Autoimmune Disease Model

MRT-6160 inhibits disease progression in a mouse model of multiple sclerosis



MRT-6160-mediated activity correlates with VAV1 levels



42

T-cell mediated experimental autoimmune encephalitis (EAE) model

C57BL/6 mice were immunized with MOG35-55 peptide on Day -12 then administered pertussis toxin (Days -12 and -10). Mice were assessed for disease daily. On Day 0, mice were treated with vehicle or MRT-6160 (PO QD) (left). On Day 5, the spinal cords of satellite mice were assessed for Vav1 levels by western blot (right).

Phase 1 Biomarker Strategy to Demonstrate MRT-6160 Pharmacodynamic Effects

Phase 1 SAD/MAD in Healthy Volunteers

Provide early insights into safety, PK/PD, and effects on key immunomodulatory signaling pathways

VAV1 protein degradation

- Flow cytometry on T and B cells: whole blood (WB)
- Targeted Mass Spec: PBMCs
- Potential: Mature B cell typing in MAD

Key downstream PD

- Flow cytometry for CD69 protein on T & B cells: WB
- Immunoassay for IL-2, IL-6, IL-17
- hs C-reactive protein

Phase 1 SAD/MAD study ongoing, clinical data anticipated in Q1 2025

VAV1: Unique Mechanism with Broad Potential Applications

Potential to address multiple autoimmune diseases with safe, oral therapy





Note: Chart adapted from Hosack et al., Nat Rev Immunol 2023. Drug class sales from Evaluate Pharma. 2030E sales may include sales from anticipated future approvals.

Monte Rosa Therapeutics

NEK7 Program (MRT-8102)

NEK7 is a Key Regulator of NLRP3 Inflammasomes, IL-1 and IL-18



Inflammation-driven diseases (selected examples)



Therapeutic hypothesis:

Activation of the NLRP3 inflammasome critically depends on NEK7

- NEK7 licenses NLRP3 assembly in a kinase-independent manner
- NEK7-deficient macrophages are severely impaired in IL-1β and IL-18 secretion

Consequently, NEK7 degradation has the potential to become an important treatment modality for a variety of inflammatory diseases

Clinical Opportunity:

Diseases driven by IL-1 and the NLRP3 inflammasome including gout, pericarditis and other cardiovascular diseases, neurologic disorders including Parkinson's disease and Alzheimer's disease, and obesity

NEK7 MGD Has Potential to Resolve Inflammation by Inhibiting Pyroptosis



MRT-8102 is a Potent, Selective NEK7-Directed MGD With a Favorable Drug-like Profile

NEK7 Ternary Complex (Crystal Structure)



MGD Activity Profile	
CRBN Binding (HTRF, IC_{50})	0.2 µM
NEK7 Degradation (CAL51, DC_{50}/Dmax)	10 nM / 89%
Selectivity (TMT proteomics)	Excellent selectivity profile in different cell lines
Physicochemical Properties	
LogD	1.47
MW	<450
Thermodynamic Solubility	166 µM
ADMET Profile	
Oral Bioavailability	Yes
Metabolite Profile (*in vitro*)	No unique human metabolites or GSH adducts (mics)
Safety Pharmacology	
Mini-Ames	Negative
hERG (patch clamp)	No inhibition (EC50> 30 µM)
Counterscreens (panel with 44 proteins)	No inhibition

MRT-8102 is a Potent, Durable, and Highly Selective NEK7-directed MGD

MRT-8102 potently suppresses inflammasome activation in primary human macrophages



MRT-8102 exposure results in prolonged PD effect



MRT-8102 induces highly selective NEK7 degradation



No degradation of other known CRBN neosubstrates

in vitro data	
CRBN binding, IC_{50}	200 nM
Degradation, DC_{50} /D_{max} (CAL51)	10 nM / 89 %

ADMET profile	
hERG	No inhibition
Oral bioavailability	Yes

MRT-8102 Leads to Potent Inhibition of NLRP3 Inflammasome in Human and Cynomolgus Monkey Cells *In Vitro*

Reduced IL-1β in human and cynomolgus monkey whole blood



LPS + Nigericin

Reduced ASC speck formation in human whole blood



Gating strategy: Single cells_CD45+_CD66b-_CD14+

Suppression of *Ex Vivo* Inflammasome Activation Following Degradation of NEK7 After Single and Multi-dose Study in Non-human Primates

MRT-8102 induces degradation of NEK7 *in vivo* over several days



No clinical observations reported

***In vivo* NEK7 degradation leads to inhibition of NLRP3 inflammasome in *ex vivo* stimulation assay**



- IL-1β in plasma after *ex vivo* stimulation with LPS + nigericin
- Similar results for Caspase-1 activity from same study
- Follow-up study with 1 mg/kg MRT-8102, *i.v.* at 4 hr showed similar results

MRT-8102 Displays Significant Blood Brain Barrier Penetration

MRT-8102 displays CNS-penetrance

Single dose p.o.



single-dose MRT-8102 p.o.
n=2 cynomolgus monkey (one male and one female)

Significant NEK7 degradation in various brain regions 24h post treatment

PBMCs



Brain

Daily dose of 30 mg/kg MRT-8102 for 7 days
Analysis on day 8 (24 hr post-final dose) by JESS Simple Western

NLRP3/NEK7 Involvement in a Broad Range of Inflammatory Diseases

Potential for groundbreaking approaches to intractable medical problems

Immuno-cardiology

Pericarditis
Myocardial infarction
Myocarditis
Heart failure

Neuro-immunology

Parkinson's disease
Alzheimer's disease

Rheumatology

Gouty arthritis
Osteoarthritis

Metabolism

Obesity

Monte Rosa Therapeutics

CDK2 Program

CDK2 is a Key Driver of Cell Cycle Progression in Cancer

CDK2: a key cell cycle regulator



Therapeutic hypothesis:

- CDK2 is a key driver of cancers with cyclin dependent kinase pathway alterations
- MGDs will achieve greater selectivity against other CDKs and kinases in general, as well as more sustained pathway inhibition compared to inhibitors

Clinical Opportunity:

- ER positive breast cancer pre and post treatment with CDK4/6 inhibitors (~474K patients)
- Ovarian cancer (~64K patients), endometrial cancer (~124K patients) and other tumors with CCNE1 amplification

Patient diagnosed incidence #s, major markets (US, EU and JP): Decision Resources Group (DRG)

MRT-9643 is a Potent, Highly Selective CDK2 MGD with a Favorable Drug-like Profile

CDK2 ternary complex (Cryo-EM)



CDK2-MGD-CRBN-DDB1 cryo-EM structure
(DDB1 not shown)

MGD Activity Profile	
CRBN Binding (HTRF, IC_{50})	0.3 µM
CDK2 Ternary Complex (HTRF, EC_{50})	6 nM
CDK2 Degradation (HEK, DC_{50}/Dmax)	56 nM / 64%
Selectivity (TMT proteomics in MCF7)	Large CDK2 selectivity window
Physicochemical Properties	
LogD	3.2
MW	511.45
kinetic Solubility	79 µM
ADMET Profile	
Oral bioavailability (all species)	nd
Metabolite Profile (*in vitro*)	No unique human metabolites and 0.52% GSH adducts (mics)
CYP DDI (5 isoforms)	IC_{50} 15 - > 50 µM
Safety Pharmacology	
Mini-Ames	Negative
hERG inhibition (patch clamp)	4.4 µM
Counterscreens (panel with 98 targets)	Not done

MRT-9643 is a Potent and Highly Selective CDK2-directed MGD

MRT-9643 is a potent CDK2-directed MGD



in vitro data	
CRBN binding, IC_{50}	289 nM
Ternary complex, EC_{50}	6 nM
Degradation, DC_{50} / D_{max} (HEK 293)	56 nM / 64 %

MRT-9643 induces highly selective CDK2 degradation and has a favorable ADME/DMPK profile



TMT Proteomics (24 hr/1 µM), MCF7 cells

No degradation of other known cereblon neosubstrates

ADMET profile	
CYP DDIs	IC_{50} 15 - >50 µM
hERG inhibition patch clamp	EC_{50} 4.4 µM
Oral bioavailability all species	nd

MRT-9643 Inhibits Proliferation of CDK2-dependent Cancer Cells

CDK2 degradation inhibits proliferation



WB degradation (24 hr) MDA-MB-157
CyQuant proliferation assay (7 d) MDA-MB-157

CDK2 degradation arrests CDK2-dependent cells in G1 phase



Cell cycle analysis (DAPI and EdU)
MDA-MB-157 (24 hr)

CDK2 degradation results in reduction of E2F pathway proteins



TMT Proteomics (24 hr/1μM)
MDA-MB-157

MRT-9643 Displays Superior Selectivity Compared to Clinical CDK2 Inhibitors

Clinical-stage CDK2 inhibitors demonstrate off target activity in biochemical kinome profiling



Carna Mobility Shift Assay; 1 µM CDK2i or CDK2 MGD, across 323 human kinases

CDK2 inhibitors but not CDK2 MGDs display activity in CDK2-independent RB1 KO line



7-day CyQuant Assay; MDA-MB-157 cell line

MRT-9643 Demonstrates Activity as Single Agent and in Combination with CDK4/6 Inhibitor in ER+ Breast Cancer

MRT-9643 induces strong TGI in combination with CDK4/6 inhibitors *in vivo*



MRT-9643 induces robust tumor regression in combination with CDK4/6 inhibition and Fulvestrant



Efficacy evaluation in MCF7 CDX Model
(MRT-9643 dosed at 30 mpk BID)

Monte Rosa Therapeutics

CCNE1 Program

CCNE1 (Cyclin E1) is a Target for Solid Tumors with Deregulated Cyclin E1

Cyclin E drives multiple hallmark cancer mechanisms



Therapeutic hypothesis:

CCNE1 (Cyclin E1) is a well-recognized human oncogene that drives multiple hallmarks of cancer, and has been considered undruggable

Selective degradation of cyclin E1 can target tumors with deregulated cyclin E1 (amplification or overexpression)

Clinical opportunity:

First-in-class Cyclin E1 degraders for Cyclin E1 amplified cancers

- Ovarian (~19%), endometrial (~10%), and gastric (~10%) cancer
- Breast cancer and others

CCNE1-directed MGDs Engage a Cryptic Pocket at the Target Interface

CCNE1 binds CRBN through a novel binding mode

CCNE1
MRT-1932
CRBN



MGD induces a cryptic pocket on the CCNE1 surface



MRT-50969 is a Potent and Highly Selective CCNE1-directed MGD

CCNE1 degradation leads to downstream pathway suppression



In vitro data	
CRBN binding, IC_{50}	0.15 µM
Ternary complex, EC_{50}	3 nM
Degradation, DC_{50}/D_{max}	3 nM / 94 %

Western blot, OVISE, 24h

MRT-50969 is highly selective for CCNE1



TMT Proteomics, MDA-MB-157 Rb K/O
1µM, 24h

MRT-50969 induces robust G1/S cell cycle arrest



FACS, EdU incorporation, 48h

CCNE1 MGD Sensitivity is Highly Correlated with CCNE1 Gene Dependency, Copy Number and Expression

Gene Dependency



Copy Number



mRNA Expression



5 Day CyQuant assay, 50 cancer cell line panel;
Gene dependency and genomics data from DepMap/Broad Institute

MRT-50969 Shows Superior Differential Activity in *CCNE1* Dependent Cell Lines Compared to Clinical-Stage CDK2 Inhibitors



5 Day CyQuant assay, bars indicate median GI_{50}

GI_{50} = growth inhibition 50%, the concentration of drug required to inhibit the growth of cancer cells in vitro by 50%

MRT-50969 Inhibits Tumor Growth in a CCNE1 Amplified Breast Cancer Model *in vivo*

MRT-50969 degrades CCNE1 *in vivo*



Day 28/8h and 24h PD, Western blot, HCC1569 CDX

MRT-50969 inhibits tumor growth in CCNE1 amplified breast cancer model



HCC1569 CDX, 28-day efficacy study

MRT-50969 Inhibits Tumor Growth in a CCNE1 Amplified Gastric Cancer Model *in vivo*

MRT-50969 degrades CCNE1 *in vivo*



Day 21/8h and 24h PD, Western blot, MKN1 CDX

MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model



21-day efficacy study in MKN1 CDX model

Monte Rosa Therapeutics

QuEEN™ Discovery Engine

Overcoming Past Limitations of Molecular Glue Degraders

Traditional thinking		Monte Rosa Therapeutics approach
'Target space is limited'		QuEEN™ has vastly expanded the degradable target space across a broad range of undruggable protein classes
'MGDs are identified by serendipity'		QuEEN™ enables target centric and systematic discovery of MGDs
'MGDs are not selective'		High selectivity achievable even within the same protein class, family and isoforms, mitigating off-target safety concerns
'Med Chem rules don't apply to MGDs'		AI-driven and structure-based design enable rational med chem optimization of MGDs

Our Critical Insight: Surfaces are Critical for MGD Discovery

Surfaces, not structures, mediate PPIs and targeted protein degradation



E3 ligase neosurface

Neosubstrate footprint

MGD footprint

- Rationally-designed MGDs create diverse E3 ligase neosurfaces, enabling recruitment of new targets
- Our geometric deep learning algorithms use surfaces to **predict** targets.
- Our surface-based algorithms **design** MGDs to recruit targets.
- Our platforms generate **actionable data-at-scale** to test & train ("data moat")

GlueShot: *de novo* MGD Design for Novel Targets



QuEEN™ Unique Capabilities

Breakthroughs enabling rapid discovery of potent, selective, and oral MGDs



AI/ML

In silico discovery using proprietary AI-powered algorithms

Structure-based Design

Proprietary database of protein structures to enable rapid optimization of MGD chemistry

MGD Library

Growing 50K compound library for novel degron and target space exploration



Proximity Screening

Specialized suite of biochemical, cellular and proteomics assays to assess proximity and degradation in high throughput

Proteomics

Integrated proteomics engine and database to identify novel targets and explore cellular complex formation and protein degradation



Proprietary AI/ML Engines Enable the Discovery of Reprogrammable Ligases, Neosubstrates, and Selective MGDs



QuEEN™: How it Works



Target and ligase ID

- Surface-centric discovery process

AI-powered chemistry

- Surface-aware MGD generation & optimization

Actionable data-at-scale

- Proteomics
- Virtual screens
- Structural biology
- High throughput screens

QuEEN™ Toolbox to Rapid Discovery of Oral MGDs

Predict
Target & ligase ID

fAIceit™ Ultra-fast fingerprint search for surface-based matchmaking



E3 ligase reprogrammability

fAIceit mimicry target ID

Design
AI-powered chemistry

FLASH™ virtual library



HitMan™ diverse library



GlueAID™ ADMET & synthesis



Rhapsody™ ternary complexes



Test & Train
Actionable data-at-scale

Headlong™ virtual screens

Proteomics mass-spec farm

HT library screening

Structural biology X-ray & cryo-EM

Algorithms Use MGD-focused, Moated Data to Identify Targets and Design MGDs

in silico experimentation

fAIceit mimicry
target ID

250
BILLION
Protein surface matchings

FLASH™
virtual library



37
BILLION
Virtual MGDs

Headlong™
virtual screens

651
MILLION
Compounds screened

Lab experimentation

Proteomics
mass-spec farm

37
MILLION
protein measurements

HT library screening



6.5
MILLION
MGD activity measurements

Structural biology
X-ray & cryo-EM

>125
TOTAL
Structures

Cloud First and Cloud Native

Scalable Data Lake with purpose-built data services for seamless data movement and unified governance

Monte Rosa Therapeutics

Team

World-Class Leadership

Deep expertise in molecular glue discovery, drug development and precision medicine

Markus Warmuth, M.D.
Chief Executive Officer

H3 Biomedicine
NOVARTIS

Sharon Townson, Ph.D.
Chief Scientific Officer

KYMERA
Warp Drive Bio

John Castle, Ph.D.
Chief Data and Information Officer

agenus
BIONTECH

Magnus Walter, DPhil
SVP, Drug Discovery

abbvie
Lilly

Filip Janku, M.D., Ph.D.
Chief Medical Officer

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Phil Nickson, Ph.D., J.D.
Chief Business and Legal Officer

Momenta
FISH
FISH & RICHARDSON

Jennifer Champoux
Chief Operating Officer

H3 Biomedicine
NOVARTIS

Andrew Funderburk
SVP, Investor Relations and Strategic Finance

Kendall Investor Relations
Health Advances


Thank You
Monte Rosa
Therapeutics